DR. CHARLES H MONTGOMERY M.D.
Prescription History 1689730772
Psychiatry & Neurology - Psychiatry in San Ramon, CA

NPI Status: Active since December 31, 2006

Contact Information

111 DEERWOOD RD
SUITE 360
SAN RAMON, CA
ZIP 94583
Phone: (925) 736-8584
Fax: (925) 886-3306

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CHARLES H MONTGOMERY M.D., an active Psychiatry specialist practicing in San Ramon, CA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 98 documented patient claims. Among these therapy options, the most frequently utilized medication is Bupropion Xl, which accounts for 28 claims alone.

Medication Index


Bupropion Xl

Generic Formulation: Bupropion HclSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 28
30-Day Fills 56.0
Days Supply 1,680
CA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills67.9
Peer Average Days Supply2,016
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $726.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.96

State Avg Cost Per Claim

$40.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bupropion is used to treat depression. It can improve your mood and feelings of well-being. It may work by helping to restore the balance of certain natural chemicals (neurotransmitters) in your brain.

Clonazepam

Generic Formulation: ClonazepamSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
CA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills45.8
Peer Average Days Supply1,297
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $165.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.36

State Avg Cost Per Claim

$9.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Dextroamphetamine-Amphetamine

Generic Formulation: Dextroamphetamine/AmphetamineSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 490
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply806
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $335.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.79

State Avg Cost Per Claim

$39.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills. This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.

Escitalopram Oxalate

Generic Formulation: Escitalopram OxalateSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 510
CA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills89.5
Peer Average Days Supply2,636
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $109.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.33

State Avg Cost Per Claim

$14.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.

Therapeutic Applications

Escitalopram is used to treat depression and anxiety. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain. Escitalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRI). It may improve your energy level and feelings of well-being and decrease nervousness.

Quetiapine Fumarate

Generic Formulation: Quetiapine FumarateSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 502
CA State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills75.8
Peer Average Days Supply2,143
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $69.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.29

State Avg Cost Per Claim

$39.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

Therapeutic Applications

This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. It may also improve your mood, sleep, appetite, and energy level. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.

Vyvanse

Generic Formulation: Lisdexamfetamine DimesylateSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
CA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply618
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,102.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$406.84

State Avg Cost Per Claim

$429.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Therapeutic Applications

Lisdexamfetamine is used to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. It may help to increase the ability to pay attention, stay focused, and stop fidgeting. Lisdexamfetamine may also be used to treat binge eating disorder (BED). It may help to reduce the number of binge eating days. This medication is a stimulant. It is thought to work by restoring the balance of certain natural chemicals (neurotransmitters) in the brain. This medication is not recommended for use for weight loss due to the risk of serious side effects.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. CHARLES H MONTGOMERY M.D. provides transparency into local medical care patterns within San Ramon, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Psychiatry** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.